logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (4)
  • CSV
  • BibTeX
  • EndNote
  • All Results (4)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Kala-azar elimination in India: Reflections on success and sustainability

Pandey DK, Alvar J, den Boer M, Jain S, Gill N,  et al.
2025-03-03 • International Health
2025-03-03 • International Health

The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the thresho...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

Sundar S, Alves F, Ritmeijer K, den Boer M, Forsyth C,  et al.
2025-02-25 • PLOS Neglected Tropical Diseases
2025-02-25 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in I...

The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study

Tessema SB, Hagos T, Kehasy G, Paintain L, Adera C,  et al.
2024-10-15 • PLOS Neglected Tropical Diseases
2024-10-15 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is an important public health problem, which mainly affects the poor rural dwelling communities in Low- and Middle-Income...

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...